Can and Should Value Based Pricing Be Applied to Molecular Diagnostics?

Garau, M., Towse, A., Garrison, L., Housman, L. and Ossa, D.

Research Paper
April 2012

Sign Up for OHE Updates

Why not sign up for our email updates? Around once or twice a week we will send you a round-up of the latest news, events and publications from OHE.

I'm already signed up    No thanks

Diagnostics not only facilitate health gain and cost savings, but also provide information to inform patients’ decisions on interventions and to clarify how their behaviour may affect their health. Current pricing and reimbursement systems for diagnostics, however, are not efficient and provide poor incentives for new diagnostic approaches.  Prices often are driven by administrative practice and expected production cost, rather than assessments of value.

The purpose of this paper is to discuss how a value based pricing (VBP) framework for efficient use and pricing of medicines also might be applied to diagnostics. We recommend a two-part approach. First, in the case of companion diagnostics introduced at the launch of the drug, the process would follow the new drug assessment processes. It would consider a broad range of value elements and be based on a balanced analysis of diagnostic impact. Second, for diagnostics not paired specifically with a drug at launch, review would be by a diagnostics-dedicated committee using VBP principles

View related slide presentation on assessment of co-dependent technologies.

A revised version of this paper has been published in Personalized Medicine and can be downloaded from: http://www.futuremedicine.com/doi/abs/10.2217/pme.12.99

Please cite as: Garau, M., Towse, A., Garrison, L., Housman, L. and Ossa, D., 2013. Can and should value-based pricing be applied to molecular diagnostics? Personalized Medicine, 10(1), pp.61-72.